Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human Pannexin 1 ELISA Kit (AC2453)
Cat.#: ASET-1042
Specifications
Description Human Pannexin 1 ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human Pannexin 1 concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.021 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 0.5-8 ng/mL Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1457 Human Neurogranin ELISA Kit (AC2868) Quantitative inquiry ASET-1294 Rat beta Arrestin 1 ELISA Kit (AC2705) Quantitative inquiry ASET-1567 Human VCP ELISA Kit (AC2978) Quantitative inquiry ASET-1921 Mouse Semaphorin 3c ELISA Kit (AC3332) Quantitative inquiry ASET-1992 Porcine BDNF ELISA Kit (AC3403) Quantitative inquiry ASET-2346 Human AGRP ELISA Kit (AC3757) Quantitative inquiry ASET-1975 Human SOX6 ELISA Kit (AC3386) Quantitative inquiry ASET-1136 Human HAS1 ELISA Kit (AC2547) Quantitative inquiry ASET-1181 Rat BACE1 ELISA Kit (AC2592) Quantitative inquiry ASET-1338 Human FOXO1A ELISA Kit (AC2749) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket